2 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Antithrombin III Deficiency: new trials by email Literature Review of Antithrombin III Deficiency trials Research Report on Antithrombin III Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antithrombin III in Infectious Disease Caused by COVID-19 Antithrombin III - Antithrombin III Deficiency, Covid19 | Phase 2 | Terminated | Enrique Ginzburg | 52 | 2021-07-06 | 2022-09-07 |
| Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate Plasma-derived AT-III concentrate - Antithrombin III Deficiency | Phase 2 / Phase 3 | Terminated | Instituto Grifols, S.A. | 3 | 2008-04-15 | 2026-10-07 |
COVID-19 (1) · Hematologic Diseases (1) · Hemostatic Disorders (1)
Blood Coagulation Disorders (2) · Blood Coagulation Disorders, Inherited (2) · Blood Protein Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Thrombophilia (2) · Cardiovascular Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1)
Antithrombin III (1)
Enrique Ginzburg (1) · Instituto Grifols, S.A. (1)
United States (1)
Enrique Ginzburg (1)